Benzinga | Oct 13, 2020 08:41AM EDT

Cerus Corporation Announces Five-Year FDA Contract For Development Of Next Generation Pathogen Reduction Technology To Treat Whole Blood; Contract Value Totals $11.1M

Cerus Corporation (NASDAQ:CERS) announced today it was awarded a five-year contract with the U.S. Food and Drug Administration (FDA) for the development of next-generation compounds to optimize pathogen reduction (PR) treatment of whole blood to reduce the risk of transfusion-transmitted infections. The contract value totals $11.1 million. This research is consistent with the FDA's strategy for developing proactive, foundational interventions to ensure blood safety and availability1.